Association of BRCA alteration (alt) type with real-world (RW) outcomes to PARP inhibitors (PARPi) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).

被引：0
|
作者：
Antonarakis, Emmanuel S.
Madison, Russell
Snider, Jeremy
Snow, Tamara
Sokol, Ethan
Chung, Jon
McCusker, Margaret Elizabeth
Singal, Gaurav
Alexander, Brian Michael
Castellanos, Emily
Venstrom, Jeffrey
Schrock, Alexa Betzig
Ross, Jeffrey S.
机构：
[1] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Fdn Med Inc, Cambridge, MA USA
[3] Flatiron Hlth, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5527
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Characteristics and outcome of octogenarian versus young patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) treated with ketoconazole.
    Sinibaldi, Victoria J.
    Dadon-Nachum, Michal
    Gottfried, Maya
    Maimon, Natalie
    Dovrish, Zamir
    Peer, Avivit
    Neumann, Avivit
    Sella, Avishay
    Kovel, Svetlana
    Carducci, Michael Anthony
    Eisenberger, Mario A.
    Kejzman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [22] Real-world evidence in patient-related outcomes (PROs) of metastatic castrate-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate plus prednisone (AA plus P).
    Gotto, Geoffrey
    Fradet, Vincent
    Drachenberg, Darrel
    Sabbagh, Robert
    Rendon, Ricardo A.
    Shayegan, Bobby
    Danielson, Brita Lavender
    Casey, Richard
    Chan, Katherine
    Camacho, Fernando
    Zardan, Anousheh
    Hew, Huong
    Feifer, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [23] Real-world treatment (Tx) patterns of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) in the US
    Shore, N.
    Laliberte, F.
    Ionescu-Ittu, R.
    Gayle, A.
    Amin, S.
    Yang, L.
    Payne, S.
    Mahendran, M.
    Lejeune, D.
    Yu, L.
    Burgents, J.
    Duh, M. S.
    Ghate, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S534 - S535
  • [24] Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer
    Su, Christopher T.
    Nizialek, Emily
    Berchuck, Jacob E.
    Vlachostergios, Panagiotis J.
    Ashkar, Ryan
    Sokolova, Alexandra
    Barata, Pedro C.
    Aggarwal, Rahul R.
    McKay, Rana R.
    Agarwal, Neeraj
    McClure, Heather M.
    Nafissi, Nellie
    Bryce, Alan H.
    Sartor, Oliver
    Sayegh, Nicolas
    Cheng, Heather H.
    Adra, Nabil
    Sternberg, Cora N.
    Taplin, Mary-Ellen
    Cieslik, Marcin
    Alva, Ajjai S.
    Antonarakis, Emmanuel S.
    PROSTATE, 2023, 83 (03): : 227 - 236
  • [25] Lost opportunities: the underutilization of castrate-resistant prostate cancer treatment in real-world settings
    Gatsinga, Rene
    Tan, Yu Guang
    Chen, Weiren
    Yang, Xinyan
    Tuan, Jeffrey Kit Loong
    Chua, Melvin Lee Kiang
    Chan, Johan
    Kanesvaran, Ravindran
    Tay, Kae Jack
    Chen, Kenneth
    Yuen, John Shyi Peng
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2024, 13 (09) : 1786 - 1794
  • [26] Genomic/genetic testing (GT) patterns for patients with metastatic castrate-resistant prostate cancer (mCRPC): Interim results from a real-world study in Europe (EU5)
    Leith, A.
    Ribbands, A.
    Gayle, A.
    Payne, S.
    McCrea, C.
    Yang, L.
    Burgents, J.
    Ghate, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S535 - S535
  • [27] Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig).
    Triner, Daniel
    Graf, Ryon
    Gjoerup, Ole
    Tukachinsky, Hanna
    Ross, Jeffrey S.
    Cheng, Heather H.
    Pritchard, Colin C.
    Zurita, Amado J.
    Mateo, Joaquin
    Cieslik, Marcin
    Morgan, Todd Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 186 - 186
  • [28] Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (AR) 878/875 mutations
    Stewart, T. F.
    Gedrich, R.
    Saha, J.
    Chirnomas, D.
    Edwards, M.
    Lang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1188 - S1188
  • [29] Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer.
    Hotte, Sebastien J.
    Finelli, Antonio
    Malone, Shawn
    Shayegan, Bobby
    So, Alan I.
    Canil, Christina M.
    Hew, Huong
    Park-Wyllie, Laura
    Saad, Fred
    Chi, Kim N.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [30] Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC.
    Pak, S.
    Reed, M.
    Luther, M.
    Averia, M.
    Desai, S.
    Pinski, J. K.
    Dorff, T. B.
    Quinn, D. I.
    Chan, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345